New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 6, 2012
16:09 EDTNVAXNovavax' Phase I RSV vaccine data published in Vaccine
Novavax today announced that the journal Vaccine has published the company's data from its 2011 Phase I clinical trial of its respiratory syncytial virus, RSV, fusion, F,recombinant nanoparticle vaccine candidate. The paper was authored by a team of researchers and clinicians at Novavax and Dr. Pedro Piedra of Baylor College of Medicine. Findings from the trial were announced in October 2011 and presented in September by Novavax at the Respiratory Virus Symposium,RSV 2012, meeting in Santa Fe, New Mexico.
News For NVAX From The Last 14 Days
Check below for free stories on NVAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
11:16 EDTNVAXNovavax to host analyst and investor day
Subscribe for More Information
September 16, 2014
16:09 EDTNVAXNovavax initiates Phase 2 trial of RSV F vaccine candidate
Subscribe for More Information
September 7, 2014
12:31 EDTNVAXNovavax presents data on RSV F nanoparticle vaccine induced monoclonal antibody
Novavax presented preclinical data demonstrating that antibodies generated to its RSV F-protein nanoparticle vaccine candidate bind to the site II epitope of the RSV F-protein with a higher affinity than palivizumab, Syangis, at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, in Washington, DC. In poster session 024: I-314b titled "Development and Characterization of Recombinant RSV Nanoparticle Vaccine Induced Monoclonal Antibody.", Novavax used its RSV F vaccine to generate a murine monoclonal antibody, NVX4C6, that binds to the antigenic site II on the RSV F-protein. Using Surface Plasmon Resonance, Novavax was able to compare the binding affinity of NVX4C6 and palivizumab to the antigenic site II. This experiment demonstrated that Novavax' RSV F vaccine can induce antibodies to the antigenic site II that have a higher binding affinity to the site than palivizumab. In addition, NVX4C6 was shown to have a slightly different specificity to the site II epitope and to recognize mutated site II peptide not recognized by palivizumab, suggesting that NVX4C6 may neutralize palivizumab escape mutants.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use